METHODS OF USE – SUPPOSITORIES / RECTAL USE

 

Rectal bioavailability of delta-9-tetrahydrocannabinol from various esters.                   (abst – 1991)

http://www.ncbi.nlm.nih.gov/pubmed/1666913

 

Rectal bioavailability of delta-9-tetrahydrocannabinol from the hemisuccinate ester in monkeys.  (abst – 1991)                                     http://www.ncbi.nlm.nih.gov/pubmed/1664466

 

Bypassing the first-pass effect for the therapeutic use of cannabinoids.                     (abst –1993)

http://www.ncbi.nlm.nih.gov/pubmed/8383856

 

US Patent 5389375 – Stable suppository formulations effecting bioavailability of Ɗ9 -thc

(full – 1995)                             http://www.patentstorm.us/patents/5389375/fulltext.html

 

US Patent 5508037 – Stable suppository formulations effecting bioavailability of Ɗ9 –

THC                    (full – 1996)        http://www.patentstorm.us/patents/5508037/fulltext.html

 

The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients.                                                       (abst – 1996)

http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=12

 

Topical and Systemic Cannabidiol Improves Trinitrobenzene Sulfonic Acid Colitis in Mice.          (full – 2012)  http://content.karger.com/produktedb/produkte.asp?DOI=000336871&typ=pdf

Share a link for